Dr. Abigail Jastrab is the Director of Patient Engagement and Clinical Innovation at PANTHERx Rare, where she leads strategic initiatives that elevate patient engagement, advance clinical excellence, and strengthen PANTHERx’s position as a leader in rare disease pharmacy. Since joining the organization in 2019, she has been instrumental in designing and operationalizing hyper-personalized care models that address the unique needs of individuals living with rare and complex conditions.

With a Doctor of Pharmacy degree from the Lloyd L. Gregory School of Pharmacy and a PGY1 Accredited Residency at Bayhealth Medical Center, Dr. Jastrab began her career in the inpatient setting, gaining diverse clinical experience across multiple states and healthcare environments. She holds Board Certification in Pharmacotherapy (BCPS) and has earned certifications in Antimicrobial Stewardship and Motivational Interviewing, reflecting her commitment to evidence-based care and patient-centered communication.

At PANTHERx Rare, Dr. Jastrab oversees innovative clinical program design and patient engagement strategies that integrate education, technology, and cross-functional collaboration to improve outcomes. Her work includes developing scalable frameworks for personalized support, ensuring seamless coordination across stakeholders, and addressing challenges in access and adherence—critical components for therapies with high complexity and long-term follow-up requirements. She also contributes to expanding the limited body of literature in rare disease through research and publications.

Dr. Jastrab’s expertise in building robust, customizable patient-centric models positions her as a valuable voice in discussions on cell and gene therapy (CGT). Her experience demonstrates how strong foundational approaches in rare disease care can be adapted to CGT delivery, supporting operational excellence and patient-first principles as these therapies evolve. In addition, her passion for serving underserved patient populations will be an important discussion point during the panel to contribute to the discussion of operationalizing patient centric approaches for complex therapies like CGT.